About Pricing FAQs Providers Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

A Hepatitis B With Hepatic Steatosis Study | Clinical Trials | Clareo Health

Back to clinical trial search

UNKNOWNNCT02392598

A Hepatitis B With Hepatic Steatosis Study

This is an epidemiologic study on effect of hepatic steatosis on prognosis and outcomes of patients with chronic hepatitis B.

Lead sponsor: Fatty Liver and Alcoholic Liver Disease Study Group, China•7 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Contacts

Jiangao Fan, MD

CONTACT

fattyliver2004@126.com

Shiyan Yan, MD

CONTACT

shyyan2008phd@yahoo.com

Sponsors

Lead Sponsor

Fatty Liver and Alcoholic Liver Disease Study Group, China

Collaborators

Unimed Scientific Inc.

This is a multicenter, prospective and open-enrollment epidemiologic study. All the patients with chronic hepatisis B will be enrolled in the study and followed up after 1 year, 3 years and 5 years with a visit window of +1 month.

Age

All ages

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•1. Clinically diagnosed chronic hepatitis B.
•2. Specific biopsy requirements for hepatic steatosis: qualified biopsy specimen within 6 months, \>5% hepatocytes show macrovesicular steatosis under HE staining and X10 microscope.
•3. Willing to participate in the long-term follow-up and cooperative.
•4. Able to provide informed consent file.

Exclusion Criteria

•1. Unable to provide informed consent.
•1. Any end-stage liver disease.
•2. Any malignant tumor.
•3. Any congenital liver disease such as Wilson disease.
•4. Any other serious disease of projected survival \< 5 years.

Related studies

Siemens Biomarker Multi-modality

NCT07495332 · Fatty Liver, Hepatic Steatosis

RECRUITINGPhase 1

Multiple Dose Study for a New Medication to Potentially Treat Liver Diseases

NCT06891365 · Healthy Volunteers, Hepatic Steatosis

Association of HsCAR with MAFLD and Liver Fibrosis: a Cross-sectional Study

NCT05974904 · Metabolic Dysfunction-associated Fatty Liver Disease, Hepatic Steatosis, and more

National Cohort of Patients Co-infected With Hepatitis B and Delta Viruses

NCT04166266 · Hepatitis D, Chronic, Hepatitis B, Chronic

Improved Sensitivity Detection of Serum HBsAg and HBsAg Reversion

NCT06550622 · Hepatitis B, Chronic

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: August 5, 2015Terms

Trial snapshot

StatusUNKNOWN

Phase—

Enrollment3,000

Start dateAug 2015

Last updatedAug 5, 2015

Condition

Hepatitis B, Chronic Hepatic Steatosis

Locations shown

Zhangzhou Zhengxing Hospital

Zhangzhou, Fujian

Shandong Provincial Hospital

Ji'nan, Shandong

Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital

Chengdu, Sichuan

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 5, 2015Data synced to Clareo: July 13, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions